NCT01907087已完成1 期
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 10
- 主要终点
- Motor-Language (ML) Scale Score During 300 mg Dosing Period
研究概览
简要总结
The purpose of this study is to determine whether BMN 190 is safe and effective in the treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) disease.
详细描述
The purpose of this study is to determine whether BMN 190 is safe and effective in the treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) disease. This is an open label Phase 1/2 study conducted in patients with CLN2 disease. Efficacy measures (disease rating scale and MRI) will be compared to a natural history control.
The study will be conducted under cGCP and patients will be closely monitored.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 15 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a diagnosis of CLN2 determined by TPP1 enzyme activity (dried blood spot) available at study entry. If no genotype information is available, blood will be collected for CLN2 gene analysis at baseline. In addition, blood for TPP1 enzyme activity (dried blood spot) will be collected at baseline to be analyzed centrally
- •Has mild to moderate disease documented by a two-domain score of 3- 6 on motor and language domains of the Hamburg Scale, with a score of at least 1 in each of these two domains
- •Written informed consent from parent or legal guardian and assent from subject, if appropriate
- •Has the ability to comply with protocol requirements, in the opinion of the investigator
- •Seizures are stable in the judgement of the investigator
排除标准
- •Is less than 3 years old at enrollment
- •Is 16 years old or older at enrollement
- •Has another inherited neurologic disease, e.g. other forms of CLN or seizures unrelated to CLN2 (patients with febrile seizures may be eligible)
- •Has another neurological illness that may have caused cognitive decline (e.g., trauma, meningitis, hemorrhage) before study entry
- •Requires ventilation support, except for noninvasive support at night
- •Has received stem cell, gene therapy, or ERT for CLN2
- •Has contraindications for neurosurgery (e.g., congenital heart disease, severe respiratory impairment, or clotting abnormalities)
- •Has contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip in the eye, aneurysm clip in the brain)
- •Has generalized motor status epilepticus within 4 weeks before the First Dose visit, taking care that status epilepticus is on clinical examination and not only electroencephalogram (EEG) (enrollment may be postponed)
- •Has severe infection (e.g., pneumonia, pyelonephritis, or meningitis) within 4 weeks before the First Dose visit (enrollment may be postponed)
- •Is prone to complications from intraventricular drug administration, including patients with hydrocephalus or ventricular shunts
- •Has known hypersensitivity to any of the components of BMN 190
- •Has received any investigational medication within 30 days before the first infusion of study drug or is scheduled to receive any investigational drug other than BMN 190 during the course of the study
- •Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's well being, safety, or clinical interpretability
- •Pregnancy any time during the study
研究组 & 干预措施
BMN190
Experimental
recombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
干预措施: BMN 190 (Biological)
结局指标
主要结局
Motor-Language (ML) Scale Score During 300 mg Dosing Period
时间窗: Baseline, Week 49/Last Assessment
The progression of ceroid lipofuscinosis (CLN2) disease was assessed using adapted motor and language domains of the Hamburg rating scale (ML scale score). Motor and Language are each 0 - 3 point subscales in which 3 represents best function and 0 represents loss of function. The sum of the motor and language scores (ML score, 0-6 points) was used to evaluate the loss of function.
次要结局
- Percentage Change From Baseline of Magnetic Resonance Imaging (MRI) at Week 49 During 300 mg Dosing Period: Whole Brain Volume(Baseline, Week 49)
- Percentage Change From Baseline of Magnetic Resonance Imaging (MRI) at Week 49 During 300 mg Dosing Period: Volume of Total Grey Matter(Baseline, Week 49)
- Percentage Change From Baseline of Magnetic Resonance Imaging (MRI) at Week 49 During 300 mg Dosing Period: Total White Matter Volume(Baseline, Week 49)
- Percentage Change From Baseline of Magnetic Resonance Imaging (MRI) at Week 49 During 300 mg Dosing Period: Volume of Cerebrospinal Fluid(Baseline, Week 49)
- Percentage Change From Baseline of Magnetic Resonance Imaging (MRI) at Week 49 During 300 mg Dosing Period: Whole Brain Apparent Diffusion Coefficient(Baseline, Week 49)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 DiseaseBatten DiseaseJansky-Bielschowsky DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2CLN2 DiseaseCLN2 DisorderNCT02485899BioMarin Pharmaceutical23
进行中（未招募）
1 期
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular DystrophyDuchenne Muscular DystrophyNCT06280209BioMarin Pharmaceutical18
已完成
1 期
Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe DiseasePompe DiseaseNCT01230801BioMarin Pharmaceutical22
进行中（未招募）
1 期
A Gene Therapy Study of BMN 331 in Subjects With Hereditary AngioedemaHAEHereditary AngioedemaNCT05121376BioMarin Pharmaceutical44
终止
2 期
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited AmbulationMucopolysaccharidosis IVAMorquio A SyndromeMPS IVANCT01697319BioMarin Pharmaceutical16